⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL42886 | 0.79 | — | — | |
| SCHEMBL11233962 | 0.79 | — | — | |
| SCHEMBL2472561 | 0.79 | — | — | |
| SCHEMBL1978630 | 0.79 | — | — | |
| SCHEMBL10774823 | 0.79 | — | — | |
| SCHEMBL575445 | 0.76 | — | — | |
| SCHEMBL34967 | 0.76 | — | — | |
| SCHEMBL4554897 | 0.76 | — | — | |
| SCHEMBL11041449 | 0.73 | — | — | |
| SCHEMBL1267181 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1865 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240140919-A1 | MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 | DENALI THERAPEUTICS INC. | 2024-05-02 | — | — | US | claimed |
| US-20230416205-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | TENVIE THERAPEUTICS, INC. | 2023-12-28 | — | — | US | claimed |
| EP-4247376-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | Denali Therapeutics Inc. (US) | 2023-09-27 | — | — | EP | claimed |
| US-20230278958-A1 | TRICYCLIC HETEROCYCLES | MERCK PATENT GMBH (DE) | 2023-09-07 | — | — | US | claimed |
| US-20230250072-A1 | MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 | DENALI THERAPEUTICS INC. | 2023-08-10 | — | — | US | claimed |
| CN-116507608-A | Compounds, compositions, and methods | 戴纳立制药公司 | 2023-07-28 | — | — | CN | claimed |
| US-20230174538-A1 | Tricyclic heterocycles | MERCK PATENT GMBH (DE) | 2023-06-08 | — | — | US | claimed |
| EP-4185564-A1 | TRICYCLIC HETEROCYCLES | Merck Patent GmbH (DE) | 2023-05-31 | — | — | EP | claimed |
| CN-116134016-A | Tricyclic heterocycles | 默克专利股份公司 | 2023-05-16 | — | — | CN | claimed |
| WO-2023078813-A1 | HETEROBIFUNCTIONAL MOLECULES AS TEAD INHIBITORS | MERCK PATENT GMBH (DE) | 2023-05-11 | — | — | WO | claimed |
| US-5221598-A | Vanadium pentoxide layer and overlying polyacrylamide layer | EASTMAN KODAK COMPANY (US) | 1993-06-22 | — | — | US | claimed |
| EP-0313297-B1 | PROCESS FOR PRODUCTION OF AVERMECTIN AGLYCONES AND CULTURES THEREFOR | PFIZER INC. (US) | 1993-05-19 | — | — | EP | claimed |
| EP-0276131-B1 | NON-NATURAL DEMETHYLAVERMECTINS AND PROCESS THEREFOR | PFIZER INC. (US) | 1993-04-07 | — | — | EP | claimed |
| EP-0313297-A2 | Process for production of avermectin aglycones and cultures therefor | PFIZER INC. (US) | 1989-04-26 | — | — | EP | claimed |
| CN-88100649-A | Methods for producing avermectin B and cultures thereof | — | 1988-10-26 | — | — | CN | claimed |
| EP-0284176-A2 | Process for production of avermectins and cultures therefor | PFIZER INC. (US) | 1988-09-28 | — | — | EP | claimed |
| CN-88100373-A | Avermectins and production method of culture bacteria thereof | — | 1988-08-31 | — | — | CN | claimed |
| EP-0276103-A2 | Process for production of B avermectins and cultures therefor | PFIZER INC. (US) | 1988-07-27 | — | — | EP | claimed |
| EP-0276131-A2 | Non-natural demethylavermectins and process therefor | PFIZER INC. (US) | 1988-07-27 | — | — | EP | claimed |
| EP-0139206-B1 | GAMMA-BUTYROLACTONE DERIVATIVES, PROCESS FOR PREPARING THE SAME AND IMMUNOMODULATING COMPOSITIONS CONTAINING THE SAME AS ACTIVE INGREDIENTS | MITSUBISHI KASEI CORPORATION (JP) | 1988-07-20 | — | — | EP | claimed |